Ginkgo Bioworks Holdings, Inc.: management transactions · United States · SEC (Form 4)

About Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. is a U.S.-based biotechnology company listed on the NYSE in the United States under the ticker DNA. The company is headquartered in Boston, Massachusetts, at 27 Drydock Avenue. Founded in Boston in 2008 by MIT-affiliated scientists, Ginkgo was built around a mission to make biology easier to engineer by combining biological design, software, automation, and lab infrastructure into one platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1830214/000162828026012346/R11.htm)) Ginkgo’s business model is organized around two main operating areas. The first, Cell Engineering, provides biological R&D tools and services to commercial and government customers across multiple industries, including healthcare, agriculture, industrial applications, chemicals, and materials. The second, Biosecurity, provides services designed to identify, monitor, prevent, and mitigate biological threats. Importantly, Ginkgo does not primarily sell end products to consumers; instead, it monetizes its platform, technical expertise, data capabilities, and automation stack to help customers move biological programs forward more quickly. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1830214/000162828026012346/R11.htm)) From a competitive standpoint, Ginkgo positions itself as a platform company in synthetic biology, a field where integration across robotics, computation, organism design, and experimental execution can create meaningful differentiation. The company emphasizes its Foundry platform and newer “autonomous labs” offering, placing it at the intersection of biotechnology, lab automation, and AI-enabled scientific workflows. That positioning allows Ginkgo to serve private customers while also participating in U.S. government-funded programs. ([nasdaq.com](https://www.nasdaq.com/press-release/twist-bioscience-and-ginkgo-bioworks-revise-collaboration-2025-05-08)) Recent developments have been strategically significant. In 2025, Ginkgo announced several government-related contracts and partnerships, including work with ARPA-H and a BARDA BioMaP Consortium award, underscoring its exposure to U.S. public-sector health, biosecurity, and industrial-resilience initiatives. In May 2025, the company also revised its collaboration with Twist Bioscience. Most notably, in late February 2026, Ginkgo announced its full-year 2025 results and said it had agreed to sell its Biosecurity business to a consortium of investors, turning that unit into a standalone private company while Ginkgo concentrates capital and management attention on autonomous labs. ([nasdaq.com](https://www.nasdaq.com/press-release/ginkgo-bioworks-teams-partners-arpa-h-project-stabilize-pharmaceutical-supply-chains)) For investors, the key theme is execution: Ginkgo remains a growth-oriented, restructuring-stage platform company whose medium-term value depends on commercial scaling, improved economics, and the success of its strategic pivot toward autonomous laboratory offerings in the United States.